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Abstract
Background—Obesity is a significant public health threat to children in the United States.
Aims—1) Determine the prevalence of obesity in a multi-center cohort of children with IBD; 2)
Evaluate whether overweight and obese status is associated with patient demographics or disease
characteristics.
Methods—We used data from the ImproveCareNow Collaborative for pediatric IBD, a multi-
center registry of children with IBD, collected between April 2007 and December 2009. Children
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ages 2-18 years were classified into BMI percentiles. Bivariate analyses and multivariate logistic
regression were used to compare demographic and disease characteristics by overweight
(BMI>85%) and obese (BMI>95%) status.
Results—The population consisted of 1598 children with IBD. The prevalence of overweight/
obese status in pediatric IBD is 23.6%, (20.0% for Crohn's disease (CD) and 30.1% for ulcerative
colitis (UC) and indeterminate colitis (IC)). African American race (OR 1.64, 95% CI 1.10-2.48)
and Medicaid insurance (OR 1.67, 95% CI 1.19-2.34) were positively associated with overweight/
obese status. Prior IBD related surgery (OR 1.73, 95% CI 1.07-2.82) was also associated with
overweight and obese status in children with CD. Other disease characteristics were not associated
with overweight and obesity in children with IBD.
Conclusions—Approximately 1/5 of children with CD and 1/3 with UC are overweight or
obese. Rates of obesity in UC are comparable to the general population. Obese IBD patients may
have a more severe disease course, as indicated by increased need for surgery. Sociodemographic
risk factors for obesity in the IBD population are similar to those in the general population.
Introduction
Across the United States, the prevalence of overweight and obese children has dramatically
increased over the past decade.1, 2 For the general population of United States children ages
2-19 during 2007-2008, 11.9% (95% CI 9.8%-13.9%) were at or above the 97th percentile,
16.9% (95% CI 14.1%-19.6%) were at or above the 95th percentile and 31.7% (95% CI
29.2%-34.1%) were at or above the 85th percentile of the BMI-for-age growth charts.3 With
this increase in obesity, serious comorbid conditions such as diabetes and hypertension have
also increased.4-6 Obese children are at increased risk for staying overweight or obese
throughout adulthood.5, 7 In addition to the general risks associated with overweight and
obese status, obesity may have disease-specific risks in children with IBD. Prior studies in
adults with IBD have shown increased morbidity, increased disease activity and more
frequent perianal complications associated with obesity.8 Furthermore, obesity-related
comorbidities may also contribute to long-term IBD morbidity and mortality as well as
contribute to polypharmacy and possible medication interactions. Little is known about the
prevalence and role of overweight and obesity among the sub-population of children with
inflammatory bowel diseases (IBD).
Traditionally, children with IBD have been described as malnourished and underweight. In a
previous study of body mass index (BMI) among those with juvenile onset IBD in Great
Britain from 1968-1983, BMI was found to be lower than that of the general population.9
However, in a more recent study of North American children with newly diagnosed IBD
from 2001-2005, approximately 10% of children with Crohn's disease and 20-30% of
children with ulcerative colitis had a BMI consistent with overweight or at risk for
overweight status at the time of IBD diagnosis.10 Rates of obesity in the treated pediatric
IBD population remain unknown. Furthermore, rates of obesity within the general
population have changed since this time, and such secular trends may similarly affect
children with IBD.
We therefore aimed to determine the prevalence of obesity among a multi-center cohort of
children with IBD and to evaluate whether overweight and obese status is associated with
patient demographics or disease characteristics.
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We performed a cross-sectional study of children with IBD enrolled in the
ImproveCareNow collaborative for pediatric IBD. The collaborative has enrolled and
prospectively followed children with previously and newly diagnosed IBD since April 2007.
Demographic information was collected at the enrollment visit, and disease characteristics
including weight and height, disease phenotype, medications, surgeries, presence of
perirectal disease, and physician's global assessment of current disease were recorded at all
visits. In this analysis, we included all patients, between the ages of 2 and 18 years of age,
who were enrolled at actively participating centers (see appendix A) and had at least 2
documented visits between April 1, 2007 and December 31, 2009 in which height, weight
and disease specific factors were measured and recorded. Patients were excluded if there
was >10% reduction in height or >20% change in BMI at follow up visit, as this was felt to
represent measurement error.
Determination of Outcome of Overweight and Obesity
Excess weight in children ages 2-19 is defined by BMI in relation to the 2000 Centers for
Disease Control and Prevention (CDC) sex-specific BMI-for-age growth charts.11 The most
recent expert committee guidelines on childhood obesity have labeled children aged 2
through 19 years with a >95th BMI percentile as obese and children between the 85th and
95th BMI percentiles as overweight.12 Therefore, for this study, we adapted BMI-for-age-
percentiles for girls and boys ages 2-18 from the CDC percentile data values. Overweight
status and obesity were defined by 3 levels: at or above the 85th percentile for BMI-for-age
(overweight), at or above the 95th percentile (obese), or at or above the 97th percentile
(severe obesity). These cut points have been used previously in the literature and coincide
with expert guidelines.3 BMI cut points were analyzed by sub-category and also in a
dichotomous fashion: overweight or obese (≥85th percentile) versus non-overweight or
obese (≤85th percentile). For all children with results >97th percentile or <3rd percentile,
individual sites were contacted to manually confirm height and weight measurements and
units. Of the 131 records selected for auditing, only 4 errors (3%) were identified and
corrected. Two charts could not be located. For each child, the most recent visit with height
and weight data was used to calculate the BMI-for-age percentile.
Determination of Exposures
For each participant, demographic characteristics such as age, self-reported race, and
insurance status were recorded. We additionally asked information on self-perceived
ethnicity. Clinical characteristics of IBD were also obtained, including disease type [Crohn's
disease (CD), Ulcerative colitis (UC) or indeterminate colitis (IC)], disease duration (defined
as years from onset of disease to most current visit), disease phenotype (for CD), prior IBD
related surgeries, presence of perianal disease on physical exam, and physician global
assessment of disease status (inactive, mild, moderate or severe). Diagnosis of CD, UC or IC
was made based on all available radiologic, pathologic and endoscopic information. Disease
assessment was performed at each visit, and a diagnosis could be revised to another IBD
subtype at subsequent visits. Physician global assessment has been shown to correlate with
both the Pediatric Crohn's Disease Activity Index (PCDAI) and the short PCDAI in the data
from this collaborative.13 Immunosuppressive medication use and corticosteroid use was
also recorded from the most recent clinic visit where height and weight was assessed, in
order to determine the effects of particular medications on BMI percentiles.
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Bivariate analyses were used to compare patient demographic characteristics and disease
factors between overweight and obese children and non-overweight and obese children with
both Crohn's disease (CD) and ulcerative colitis (UC) or indeterminate colitis (IC).
Prevalence of various categories of BMI-for-age percentiles, including underweight, normal
and overweight ranges of percentiles, in the IBD population by disease subtype were then
compared. Multivariable logistic regression modeling was used to identify the independent
effects of demographic and disease characteristics on overweight and obese status among
children with IBD and by CD or UC/IC subtype. Variables were selected for the models a
priori based on the prior literature.
For all analyses, p-values were two-sided, and a p-value of 0.05 or less was considered
statistically significant. All statistical analyses were performed using STATA Version 9.0
(College Station, TX). The study protocol was approved by all sites participating in the
collaborative, and informed consent was obtained if required by institutional review boards.
Results
The initial database contained data on 2042 children aged 2-18 years with IBD from actively
enrolling sites. Of these, we excluded 417 children due to the lack of at least 2 separate
measurements of height and weight and 46 children with >10% reduction in height, or >20%
change in BMI between subsequent visits. One additional child was excluded, as there was
no initial diagnosis of CD, UC or IC. Only 45 patients (2.8% of population) changed IBD
subtype at subsequent visit. The final study population included 1598 children.
Table 1 demonstrates the demographic and clinical characteristics of children with CD by
overweight or obese status. Those children who were overweight or obese were more likely
to be of a non-Caucasian race and to have Medicaid insurance (as a marker for
socioeconomic status). Younger age was also statistically associated with overweight and
obese status, although the absolute magnitude of this difference was small (median 14 years
versus 15 years). Table 2 shows similar characteristics among children with UC or IC. The
only significant differences in this group were that overweight or obese children with UC or
IC were more likely to have Medicaid insurance or to use methotrexate. There was also a
non-significant increase in prednisone and infliximab use among obese or overweight
children with UC/IC.
Overall, the prevalence of overweight or obesity among children with CD was 20.0%. This
rate was higher (30.1%) among children with UC or IC. In the overall IBD population, the
prevalence was 23.6%. Table 3 shows further breakdown of BMI-percentiles in children
with CD or UC/IC. Children with UC/IC had greater rates of overweight, obese and severely
obese than patients with CD. The rate of overweight and obesity in children with UC/IC
more closely mirrored the reported rate in the general population. Patients with CD had
relatively greater percentages of underweight children when compared to patients with UC/
IC (Table 3).
Additional analyses were performed, limiting the population to only those children who
were enrolled in the collaborative within 90 days of their initial IBD diagnosis (n=426, 277
with CD, 149 with UC/ IC). The prevalence of overweight and obesity in this group was
essentially unchanged from the entire study population, 20.9% among patients with newly
diagnosed CD and 34.9% among patients newly diagnosed with UC/IC. We then
investigated the population of patients who reported Hispanic ethnicity, as this is a risk
factor for overweight and obesity in the general population. The prevalence of overweight
and obesity for the Hispanic population with IBD was 35.2% as compared to 23.1% among
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the non-Hispanic IBD population (p=0.02). By disease sub-type, the prevalence of
overweight and obesity was 30.6% for CD and 40.0% for UC/IC in the Hispanic population.
We finally performed a subanalysis further investigating any corticosteroid use. We defined
any corticosteroid use as use at either the enrollment or most recent visit, in order to account
for prior corticosteroid use. Among patients with CD, there was no difference in the rate of
overweight and obesity (20.5% for those with any use of corticosteroids at prior or current
visit, and 19.7% for non-users, p=0.8). A significant difference was found among patients
with UC, with a rate of overweight and obesity of 35.0% for those with any use of
corticosteroids at prior or current visit, as compared to 27.1% for non-users (p=0.05).
The independent effects via multivariate analysis of demographic and disease characteristics
on overweight and obese status in children with IBD, presented overall and stratified by CD
or UC/IC, are shown in table 4. On adjusted analyses for patients with IBD and among the
CD population, African American race and having Medicaid insurance, rather than
commercial insurance, were significantly associated with overweight and obese status.
Among UC patients, the association between African American race and Medicaid
insurance and overweight/obese status did not reach statistical significance. Among patients
with CD, prior surgery was significantly associated with overweight and obesity (adjusted
OR 1.73 95% CI 1.07-2.82). In patients with CD, thiopurine use was inversely associated
with overweight and obese status (adjusted OR 0.68 95% CI 0.48-0.98). No other clinical
disease characteristics were associated with overweight and obesity in children with IBD.
Analyses were repeated with BMI-percentile as a continuous variable, and the independent
effects of predictors were found to be similar (data not shown).
Discussion
Childhood obesity has become an epidemic in the United States, with an estimated 31.7%
meeting the definition of overweight or obese.3 The results of this study indicate that a
substantial proportion of children with IBD, particularly UC or IC, are also either
overweight or obese. This is important, as obesity may be associated with increased
complications of disease and also with long-term cardiovascular and metabolic
complications. In the adult IBD population, obesity has been associated with shorter time to
development of perianal complications, more active disease, and more frequent
hospitalizations.8 Furthermore, obesity-related comorbidities may indirectly affect IBD-
related morbidity and mortality, as well as increase the potential for polypharmacy and
medication interactions. The pathophysiology of obesity supports the association with
increased severity of disease. Obesity can be considered a chronic low-grade state of
inflammation. In obesity, adipose tissue can undergo a transformation and become infiltrated
by macrophages.14 In addition, many pro-inflammatory markers linked to obesity and
adipose tissue (including leptin, adiponectin, resistin and ghrelin) have also been linked to
IBD.15, 16 These markers may become upregulated, contributing to disease activity.
The results of this study are consistent with the results of a previously published study of
newly diagnosed (untreated) CD and UC from two separate North American cohorts
initiated in 2000. Kugathasan et al found that most children with CD or UC had a BMI
percentile in the normative range. However, 10% of children with CD and 20-30% of
children with UC were overweight or at risk for overweight (with new consensus definition,
this would represent overweight or obese).10 In the present study of treated IBD, we found
even greater rates of overweight and obesity. Similar to Kugathasan et al, we also found
higher rates of overweight and obesity among children with UC/IC as compared to CD,
although CD patients still had a 20% prevalence of overweight or obesity.
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Similar to adult IBD populations,8 the results of this study also indicate that pediatric
patients with CD who are either overweight or obese have had higher rates of IBD related
surgery. In UC/IC, this trend did not reach statistical significance. These pediatric data, in
combination with prior adult data, suggest that obesity in IBD may be an independent
predictor of a more complicated disease course.
The early literature on pediatric IBD found associations between weight and growth
retardation and juvenile onset of IBD, especially CD. 9 Malnutrition is even a component of
the most commonly used disease severity indices in CD, the Crohn's Disease Activity Index
(CDAI) and the Pediatric Crohn's Disease Activity Index (PCDAI). Since the earliest
descriptions of IBD, a greater number of medications have become available for treatment
and both CD and UC may be recognized earlier in the course of the disease. For these
reasons, malnourishment may no longer be a common manifestation of treated pediatric
IBD. Rather, children with IBD may now be following the course of the rest of the
population, with a greater percentage overweight or obese than ever before.
The factors we found to be associated with overweight and obesity, including non-Caucasian
race and Medicaid insurance status (a proxy for lower socioeconomic status), have also been
shown to be associated with overweight and obesity in the general pediatric population.3 We
also found thiopurine use to be inversely associated with overweight and obesity in patients
with CD. We speculate that current thiopurine use may be a marker for prior disease severity
associated with malabsorption. Environmental factors such as excess energy consumption
and decreased physical activity can exacerbate the tendency towards obesity in all children,4
regardless of chronic disease status. Appropriate lifestyle interventions for obesity, including
dietary modifications and increased physical activity, are important for all overweight or
obese children, including those with IBD.
Surprisingly, we found few associations between current medication use and overweight and
obese status. Current prednisone use was not associated with overweight and obese status in
CD, although a non-significant trend was observed in UC. Perhaps, this reflects the fact that
prednisone use was reserved for the treatment of more severe disease, the population of
patients which might have had the lowest BMI prior to corticosteroid initiation.
Alternatively, it may only be prior use of corticosteroids that is associated with overweight
and obese status, as the weight gain occurs over time. We did account for prior
corticosteroid use in subanalyses (corticosteroid use at the time of enrollment or subsequent
visit). We were unable to account for all prior corticosteroid use, as we only had information
on current use at the time of visit. This may have contributed to the lack of association in
patients with CD. We did find a significant increase in the prevalence of overweight and
obesity in patients with UC/IC on prior or current corticosteroids. Of note, we also found a
small and non-significant association between current infliximab use and overweight and
obese status, an observation often noted in clinical practice.
There are several strengths to this multi-center study. We were able to study a large number
of children with IBD, allowing for more precise estimates of BMI percentiles. The centers
included in the Improve Care Now collaborative represent a mixture of private, not-for-
profit, and academic centers of various sizes and from all regions of the United States,
increasing the generalizability of these results. The database also contained extensive data
on clinical disease characteristics, including duration of disease, phenotype, assessment of
severity, and prescribed medications. Therefore, we were able to control for many potential
confounders of the relationship between IBD and overweight and obese status.
There are several limitations to this study. The cross-sectional design of this analysis
precludes definitive causal inferences regarding associations between BMI and specific
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disease characteristics or medication utilization. In addition, confirmation of clinical
variables in the database, other than anthropometrics, was beyond the scope of this study.
However, we did ask sites to confirm outlying height and weight measurements, and found
these to be remarkably accurate with very few errors (<3%). Also, the proportion of
overweight and obesity in any given population will vary according to where the continuous
variable for BMI is dichotomized. We did perform additional analyses using BMI-percentile
as a continuous variable and found similar results. A priori, we chose to use standard
definitions of overweight and obesity consistent with the CDC BMI-for-age growth charts.
Use of other standards might result in other proportions, but would be unlikely to
significantly change the independent effects of demographic and disease characteristics seen
in our model.
In summary, overweight and obesity are common in pediatric IBD. Little is still known
about how childhood obesity will affect the adult outcomes of patients with IBD. The results
of this study have important implications for the care of children with IBD. It is important
for providers to recognize that CD and UC/IC can exist in overweight and obese patients,
and that the traditional description of malnourishment in pediatric IBD may no longer
represent the majority of cases. Because gastroenterologists have unique expertise in
nutrition and improved access to dieticians and other multidisciplinary resources, screening,
counseling, and treatment for overweight and obesity should be the standard of care for the
patient with IBD. Lifestyle modifications, including dietary modification and physical
activity, are important for all overweight and obese children, including those with IBD.
Further studies on the relationship between obesity and inflammation in the pediatric
population are warranted.
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Appendix A
Actively Enrolling Sites in the ImproveCareNow Pediatric IBD Collaborative
1. Nationwide Children's Hospital, Columbus, OH
2. Inova Pediatric Digestive Disease Center, Fairfax, VA
3. Nemours Children's Clinic
4. University of North Carolina at Chapel Hill, Chapel Hill, NC
5. The Barbara Bush Children's Hospital, Portland, ME
6. Loyola University, Chicago, IL
7. University of Oklahoma, Oklahoma City, OK
8. University of Vermont, Burlington, VT
9. Emory University, Atlanta, GA
10. Children's Medical Center of Dallas, Dallas, TX
11. Pediatric Gastroenterology & Nutrition Associates, Las Vegas, NV
12. Massachusetts General Hospital, Boston, MA
13. Oakland Children's Hospital, Oakland, CA
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